XTNT icon

Xtant Medical Holdings

0.6310 USD
+0.0099
1.59%
At close Updated Sep 12, 4:00 PM EDT
1 day
1.59%
5 days
-2.83%
1 month
-5.82%
3 months
-2.92%
6 months
29.57%
Year to date
34.8%
1 year
4.75%
5 years
-28.16%
10 years
-98.43%
 

About: Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.

Employees: 232

0
Funds holding %
of 7,462 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

50% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 4

31% more capital invested

Capital invested by funds: $45.3M [Q1] → $59.1M (+$13.8M) [Q2]

17% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 6

7% more funds holding

Funds holding: 28 [Q1] → 30 (+2) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

11.87% less ownership

Funds ownership: 69.27% [Q1] → 57.39% (-11.87%) [Q2]

Financial journalist opinion

Neutral
PRNewsWire
9 days ago
Xtant Medical to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
BELGRADE, Mont. , Sept. 4, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and woundcare disorders, today announced that Sean Browne, CEO, and Scott Neils, CFO, will be participating in the H.C.
Xtant Medical to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Neutral
Seeking Alpha
1 month ago
Xtant Medical Holdings, Inc. (XTNT) Q2 2025 Earnings Call Transcript
Xtant Medical Holdings, Inc. (NYSE:XTNT ) Q2 2025 Earnings Conference Call August 12, 2025 8:30 AM ET Company Participants Scott C. Neils - Chief Financial Officer Sean E.
Xtant Medical Holdings, Inc. (XTNT) Q2 2025 Earnings Call Transcript
Neutral
PRNewsWire
1 month ago
Xtant Medical Reports Second Quarter 2025 Financial Results
Total Revenue of $35.4 Million Increased 18% Year-over-Year Delivers Positive Net Income, Adjusted EBITDA and Operating Cash Flow Raises FY25 Revenue Guidance to $131-$135 Million, Representing Growth of 11%-15% over FY24 BELGRADE, Mont. , Aug. 12, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and woundcare disorders, today reported financial and operating results for the second quarter ended June 30, 2025.
Xtant Medical Reports Second Quarter 2025 Financial Results
Neutral
PRNewsWire
1 month ago
Xtant Medical to Attend the CG 45th Annual Growth Conference
BELGRADE, Mont. , Aug. 6, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and woundcare disorders, today announced that Sean Browne, CEO and Scott Neils, CFO will be attending the following upcoming conference: Event: CG 45th Annual Growth Conference Date: August 12, 2025 at 3:30pm ET Location: Boston, MAFormat: 1x1 Meetings & Presentation For more information, please visit: https://wsw.com/webcast/canaccord108/xtnt/2576418  About Xtant Medical Holdings, Inc. Xtant Medical's mission of honoring the gift of donation so that our patients can live as full and complete a life as possible, is the driving force behind our company.
Xtant Medical to Attend the CG 45th Annual Growth Conference
Neutral
PRNewsWire
1 month ago
Xtant Medical to Announce Second Quarter 2025 Financial Results on August 12, 2025
BELGRADE, Mont., Aug. 5, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and woundcare disorders, today announced that it will release its financial results for the second quarter ended June 30, 2025, before the start of trading on Tuesday, August 12, 2025.
Xtant Medical to Announce Second Quarter 2025 Financial Results on August 12, 2025
Neutral
PRNewsWire
2 months ago
Xtant Medical Announces Definitive Agreements for the Sale of its Coflex® and CoFix® Spinal Implants and All OUS Businesses to Companion Spine
Transaction expected to facilitate enhanced focus on Xtant's core businesses Total consideration of approximately $19.2 million allows Xtant to reduce outstanding debt and improve liquidity BELGRADE, Mont. , July 8, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and woundcare disorders, today announced that the company has entered into agreements to sell certain Coflex® and CoFix® interlaminar stabilization implant assets and all OUS entities of Paradigm Spine GmbH, to Companion Spine, LLC, a French-American company fully dedicated to posterior dynamic spine stabilization and motion preservation systems for the treatment of spine and back pain.
Xtant Medical Announces Definitive Agreements for the Sale of its Coflex® and CoFix® Spinal Implants and All OUS Businesses to Companion Spine
Neutral
PRNewsWire
3 months ago
Xtant Medical Announces the Launch of OsteoFactor Pro™
Allogeneic Growth Factor Solution to Accelerate Bone Repair BELGRADE, Mont. , May 28, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic and wound care disorders, today announced the commercial launch of OsteoFactor Pro™, a naturally occurring cocktail of allogeneic growth factors engineered to improve bone healing and support surgical success across orthopedic and spine procedures.
Xtant Medical Announces the Launch of OsteoFactor Pro™
Neutral
Seeking Alpha
4 months ago
Xtant Medical Holdings, Inc. (XTNT) Q1 2025 Earnings Call Transcript
Xtant Medical Holdings, Inc. (NYSE:XTNT ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Brett Maas - Hayden IR Sean Browne - President and Chief Executive Officer Scott Neils - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Ryan Zimmerman - BTIG Operator Good afternoon, everyone, and welcome to the Xtant Medical's First Quarter 2025 Financial Results. At this time, all participants are in a listen-only mode, and the floor will be open for questions following the presentation.
Xtant Medical Holdings, Inc. (XTNT) Q1 2025 Earnings Call Transcript
Neutral
PRNewsWire
4 months ago
Xtant Medical Reports First Quarter 2025 Financial Results
Revenue Increases 18% Year-over-Year Delivers Positive Net Income and $1.3 Million in Operating Cash Flow Increases 2025 Revenue Guidance to $127 Million to $131 Million BELGRADE, Mont. , May 12, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and wound care disorders, today reported financial and operating results for the first quarter ended March 31, 2025.
Xtant Medical Reports First Quarter 2025 Financial Results
Neutral
PRNewsWire
4 months ago
Xtant Medical to Issue First Quarter 2025 Financial Results on May 12, 2025
BELGRADE, Mont. , May 6, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic and woundcare disorders, today announced that it will release its financial results for the first quarter ended March 31, 2025, after the close of the financial markets on Monday, May 12, 2025.
Xtant Medical to Issue First Quarter 2025 Financial Results on May 12, 2025
Charts implemented using Lightweight Charts™